Ozempic, Wegovy And Mounjaro

GLP1 stands for glucagonlike peptide1, a hormone your body naturally makes to help control blood sugar after you eat. These medications work by:

• Helping the body release more insulin
• Lowering blood sugar levels
• Slowing how fast food moves through the stomach
• Reducing appetite and increasing feelings of fullness

There are two main types of GLP1 drugs involved in current lawsuits. GLP1 receptor agonists, such as Ozempic, Wegovy, and Rybelsus, contain semaglutide. Dualaction GLP1 drugs, such as Mounjaro and Zepbound, contain tirzepatide, which affects two hormones and may have stronger effects on digestion and weight loss.

While these drugs are approved to treat diabetes and support weight loss, reports show they may cause serious and sometimes permanent injuries in some users

Reported side effects include:

• Gastroparesis (Stomach Paralysis): The stomach slows or stops digestion, leading to ongoing nausea, vomiting, bloating, and trouble eating.
• Intestinal Obstruction (Ileus): A dangerous blockage that can cause severe pain, vomiting, and may require emergency surgery.
• NAION (Sudden Vision Loss): A rare eye condition that can cause permanent vision loss, often without warning.
• Blood Clots (DVT and Pulmonary Embolism): Clots that may form in the legs and travel to the lungs, which can be lifethreatening.

Many lawsuits claim these risks were not clearly disclosed to patients before the drugs were widely prescribed.